Browsing Tag

PLK1 inhibitor

Cyclacel Pharmaceuticals to Present at Biotech Showcase and Participate in a…

Eli Pacheco Dec 16, 2022 0

BERKELEY HEIGHTS, N.J., Dec. 15, 2022 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing…

Health

Cyclacel Hosting Research & Development Day

Eli Pacheco Oct 24, 2022 0

-Program Update on its CDK2/9 Inhibitor, Oral Fadraciclib, and Oral PLK1 Inhibitor, CYC140, for the Treatment of Advanced Solid Tumors and Lymphoma- -Monday, October 31st @ 10 am ET-…

Health

Cyclacel Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides…

Eli Pacheco Aug 11, 2022 0

- Oral fadraciclib demonstrated good tolerability with continuous dosing; anticipate entering Phase 2 POC stage in 2H 2022 – - Demonstrated evidence of target engagement for…

Health

Cyclacel Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides…

Eli Pacheco May 12, 2022 0

- Oral Fadraciclib Demonstrating Strong Safety Profile with Continuous Dosing; anticipate entering Phase 2 POC in 2H 2022 - - First Patients Dosed in Phase 1/2…